Multivariable Risk Score Beneficial for Identifying Clinically Significant Prostate Cancer

THURSDAY, June 25, 2026-- Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors offers greater clinical net benefit for detecting clinically significant prostate cancer (csPC)...